Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	212.38	99.59	102.83	155.58	42.3
Short-Term Investments	662.27	617.99	374.54	268.97	154.67
Cash & Short-Term Investments	874.65	717.58	477.37	424.55	196.97
Cash Growth	21.89%	50.32%	12.44%	115.55%	54.31%
Accounts Receivable	-	-	0.1	0.1	0.45
Other Current Assets	19.58	20.88	9.01	6.52	2.75
Total Current Assets	894.23	738.46	486.48	431.17	200.16
Net Property, Plant & Equipment	3.65	3.44	3.34	2.94	2.06
Other Long-Term Assets	1.54	0.5	0.6	0.98	1.49
Total Assets	899.42	742.4	490.42	435.09	203.71
Accounts Payable	8.68	2.14	2.24	14.23	2.33
Accrued Expenses	62.01	45.73	24.11	18.83	11.02
Unearned Revenue	-	-	0.29	0.29	0.29
Total Current Liabilities	70.7	47.87	26.64	33.35	13.64
Long-Term Debt	49.94	20.58	20.21	4.65	-
Other Long-Term Liabilities	56.62	2.31	1.56	2.03	2.36
Total Long-Term Liabilities	106.56	22.89	21.77	6.68	2.36
Total Liabilities	177.25	70.76	48.4	40.03	15.99
Preferred Stock	132.06	188.89	206.52	142.15	133.83
Common Stock	1.02	0.81	0.54	0.41	0.24
Additional Paid-in Capital	1,927	1,478	960.54	741.07	412.1
Accumulated Other Comprehensive Income	0.45	-0.01	0.34	-0.39	-0.16
Retained Earnings	-1,338	-995.86	-725.91	-488.17	-358.3
Shareholders' Equity	722.17	671.64	442.02	395.06	187.72
Total Liabilities & Equity	899.42	742.4	490.42	435.09	203.71
Total Debt	49.94	20.58	20.21	4.65	0
Net Cash (Debt)	824.71	697	457.17	419.91	196.97
Net Cash Growth	18.32%	52.46%	8.87%	113.19%	54.31%
Net Cash Per Share	9.72	10.27	10.21	13.09	16.53
Book Value	722.17	671.64	442.02	395.06	187.72
Book Value Per Share	8.52	9.89	9.88	12.31	15.75
Tangible Book Value	722.17	671.64	442.02	395.06	187.72
Tangible Book Value Per Share	8.52	9.89	9.88	12.31	15.75

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q